Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 ...

With the speed at which technology advances, there is little room for suboptimal performance and out-of-date tech. Precise ...

The global healthcare landscape is witnessing a transformative shift in the management of rare genetic disorders. At the forefront of this evolution stands the Hemophilia Therapeutics Market. This ...

While cleaner code is a benefit of this process, the ultimate goal is the "DevEx Dividend," a surge in productivity that impacts the bottom line by recapturing engineering capacity lost to toil. Based ...

A research team led by Prof. Seunguk Song from the Department of Energy Science at Sungkyunkwan University (SKKU), in ...

Dual-layer AI architecture and Four Turbo engines boost spectrum, energy, and O&M efficiency while unlocking new ARPU growth through experience-driven monetization ...

Spherix Global Insights today announces the release of its latest Market Dynamix™:Paroxysmal Nocturnal Hemoglobinuria (PNH) (US) 2026 study, revealing a sizable population of patients eligible for ...

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End-of-Phase 2 meeting with the U.S. Food and Drug AdministrationOn-t ...

Good afternoon, everyone, and welcome to the Atea Pharmaceuticals' Fourth Quarter 2025 Financial Results and Business Update Conference Call. [Operator Instructions] I would now like to turn the call ...

The 2026 NFL Scouting Combine continued with its third day of draft prospect testing on Feb. 28. USA TODAY Sports provided live updates.